论文部分内容阅读
目的观察复方鳖甲软肝片治疗慢性乙型肝炎对肝纤维化的改善情况与安全性.方法选择36例慢性乙型肝炎患者,口服复方鳖甲软肝片治疗24周,比较治疗前后血清肝纤维化指标与瞬时弹性波扫描仪检查(Fibroscan)所得肝脏硬度值(liver stiffness values,LSM).结果31例患者最终完成了24周疗程,治疗后血清肝纤维化指标与 LSM 值均有明显下降,具有统计学意义,未发现与治疗相关不良反应.结论复方鳖甲软肝片治疗慢性乙型肝炎肝纤维化具有较好的疗效与安全性.“,”Objective To oserve the efficacy and safety of fufangbiejiaruanganpian in treatment of liver fibrosis in patients with chronic hepatitis B Methods A total of 36 patients with chronic hepatitis B received fufangbiejiaruanganpian oraly 2.0 tid for 24 weeks .The serum liver fibrosis markers were tested before and after treatment.Al patients were checked with fibroscan to assess liver stiffness values(LSM) before and after treatment.Results 31patients finished the total treatment ,compared with pre-treatment ,al of serum liver fibrosis markers and LSM after treatment decreased obviously, the differences was statisticaly significant(P<0.05).No severe adverse reaction was found during treatment. Conclusion fufangbiejiaruanganpian is effective and safe in treatment of liver fibrosis in patients with chronic hepatitis B